Document:

Form of Performance-Accelerated Restricted Stock Unit Agreement

 Exhibit 10.1 
 PERFORMANCE–ACCELERATED 
 RESTRICTED STOCK UNIT AGREEMENT 
 Non-transferable 
 GRANT TO 

  
  
 (“GRANTEE”) 
 by PSS World Medical, Inc. (the
“Company”) of Restricted Stock Units (the “Units”) representing the right to earn, on a one-for-one basis, shares of its common stock, $0.01 par value (the “Shares”) 
 pursuant to and subject to the provisions of the PSS World Medical, Inc. 2006 Incentive Plan (the “Plan”) and to the terms and conditions set forth on the
following page (the “Terms and Conditions”). By accepting the Units, Grantee shall be deemed to have agreed to the terms and conditions set forth in this Agreement and the Plan. 
 The Units will vest and become non-forfeitable on the fifth anniversary of the Grant Date, provided, however, that the Units may vest earlier based on the Company’s
achievement of an Earnings Per Share target for the fiscal year ending             , 2012, or upon certain other events as set forth in Section 2 of the Terms and Conditions.

 IN WITNESS WHEREOF, PSS World Medical, Inc., acting by and through its duly authorized officers, has caused this Agreement to be executed
as of the Grant Date. 
  

			
	PSS WORLD MEDICAL, INC.
		
	By:	 	  

		 	Its: Authorized Officer
	
	Grant Date: June 4, 2009

 TERMS AND CONDITIONS 
 1. Defined Terms. Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. In addition, for purposes of this Agreement, “Earnings Per Share” means earnings per
diluted shares as determined by the Company in accordance with generally accepted accounting principles and reported on the year-end financial statements of the Company. 
 2. Vesting of Units. The Units have been credited to a bookkeeping account on behalf of Grantee. The Units will be earned, vested and become non-forfeitable on the earliest to occur of the following (in any
such case, the “Vesting Date”): 
 (a) the fifth anniversary of the Grant Date, provided Grantee is then still employed by the
Company or any Affiliate; 
 (b) the third anniversary of the Grant Date, provided Grantee is then still employed by the Company or any
Affiliate, and provided further, that the Company has achieved an Earnings Per Share target of             for the fiscal year ending
            , 2012; 
 (c) the termination of Grantee’s employment due to
death or Disability; or 
 (d) the occurrence of a Change in Control. 
 Earnings per share amounts will exclude the effect of recent accounting changes related to the Company’s outstanding convertible debt. 
 If Grantee’s employment terminates prior to the Vesting Date for any reason other than Grantee’s death or Disability, Grantee shall forfeit all right, title and interest in and to the Units as of the date of
such termination and the Units will be reconveyed to the Company without further consideration or any act or action by Grantee. In addition, any Units that fail to vest in accordance with the terms of this Agreement will be forfeited and reconveyed
to the Company without further consideration or any act or action by Grantee. 
 3. Conversion to Shares. Unless the Units are forfeited prior to the
Vesting Date as provided in Section 2, the Units will be converted to actual Shares on the Vesting Date (the “Conversion Date”). Shares will be registered on the books of the Company in Grantee’s name as of the Conversion Date
and delivered to Grantee as soon as practical thereafter, in certificated or uncertificated form. 
 4. Dividend Equivalents. No dividend equivalent
rights shall attach to the Units granted hereby. 
 5. Restrictions on Transfer and Pledge. No right or interest of Grantee in the Units may be
pledged, encumbered, or hypothecated or be made subject to any lien, obligation, or liability of Grantee to any other party other than the Company or an Affiliate. The Units may not be sold, assigned, transferred or otherwise disposed of by Grantee
other than by will or the laws of descent and distribution. 
 6. Limitation of Rights. The Units do not confer to Grantee or Grantee’s
Beneficiary, executors or administrators any rights of a stockholder of the Company unless and until Shares are in fact issued to such person in connection with the Units. Nothing in this Agreement shall interfere with or limit in any way the right
of the Company or any Affiliate to terminate Grantee’s employment at any time, nor confer upon Grantee any right to continue in employment of the Company or any Affiliate. 
 7. Payment of Taxes. The Company or any Affiliate employing Grantee has the authority and the right to deduct or withhold, or require Grantee to remit to the employer, an amount sufficient to satisfy federal,
state, and local taxes (including Grantee’s FICA obligation) required by law to be withheld with respect to any taxable event arising as a result of the vesting or settlement of the Units. The withholding requirement may be satisfied, in whole
or in part, at the election of the Company’s corporate secretary (the “Secretary”), by withholding from the settlement of the Units Shares having a Fair Market Value on the date of withholding equal to the minimum amount (and not any
greater amount) required to be withheld for tax purposes, all in accordance with such procedures as the Secretary establishes. The obligations of the Company under this Agreement will be conditional on such payment or arrangements, and the Company,
and, where applicable, its Affiliates will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to Grantee. 
 8. Restrictions on Issuance of Shares. If at any time the Committee shall determine in its discretion, that registration, listing or qualification of the Shares underlying the Units upon any securities exchange
or similar self-regulatory organization or under any foreign, federal, or local law or practice, or the consent or approval of any governmental regulatory body, is necessary or desirable as a condition to the settlement of the Units, the Units will
not be converted to Shares in whole or in part unless and until such registration, listing, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Committee. 
 9. Amendment. The Committee may amend, modify or terminate this Agreement without approval of Grantee; provided, however, that such amendment, modification or
termination shall not, without Grantee’s consent, reduce or diminish the value of this award determined as if it had been fully vested on the date of such amendment or termination. 
 10. Plan Controls. The terms contained in the Plan shall be and are hereby incorporated into and made a part of this Agreement and this Agreement shall be governed by and construed in accordance with the Plan.
Without limiting the foregoing, the terms and conditions of the Units, including the number of shares and the class or series of capital stock which may be delivered upon settlement of the Units, are subject to adjustment as provided in Article 10
of the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall be controlling and determinative. 
 11. Severability. If any one or more of the provisions contained in this Agreement is deemed to be invalid, illegal or unenforceable, the other provisions of this
Agreement will be construed and enforced as if the invalid, illegal or unenforceable provision had never been included. 
 12. Notice. Notices and
communications under this Agreement must be in writing and either personally delivered or sent by registered or certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to PSS World Medical,
Inc., 4345 Southpoint Blvd, Suite 250, Jacksonville, FL 32216, Attn: Secretary, or any other address designated by the Company in a written notice to Grantee. Notices to Grantee will be directed to the address of Grantee then currently on file with
the Company, or at any other address given by Grantee in a written notice to the Company.Amgen Letter Agreement

 Exhibit 10.1 
  
 

 
  

					
		  		  	 322 East Main Street
 Branford, CT 06405
 (203) 481-1104
 (203) 315-3300 Fax 
 www.curagen.com

 May 2, 2009 
 Tom Boone 
 Vice President, Protein Sciences 
 Amgen
Fremont Inc. 
 One Amgen Center Drive 
 Thousand Oaks, CA
91320-1799 
 Dear Mr. Boone: 
 Reference
is made to that certain Second Restated Collaboration Agreement between Amgen Fremont Inc. (successor in interest to Abgenix, Inc.) (“AFI”) and CuraGen Corporation (“CuraGen”) dated as of April 12, 2004 and amended
October 19, 2004 (“Collaboration Agreement”). AFI and CuraGen each may be referred to herein as a “Party” and the two collectively as the “Parties,” and capitalized terms used herein but not otherwise defined shall
have the meanings ascribed to them in the Collaboration Agreement. 
 Under the Collaboration Agreement, (A) AFI granted to CuraGen
certain licenses relating to CuraGen Products, CuraGen Optioned Antigens and CuraGen Licensed Antigens, and (B) CuraGen granted to AFI certain licenses to ABX Products, ABX Optioned Antigens and ABX Licensed Antigens. The Parties now desire to
grant to each other such irrevocable licenses as may be necessary or useful to permit each to fully develop and commercialize Products targeted to such Party’s Optioned Antigens and Licensed Antigens as described more fully below, and otherwise
to terminate the Collaboration Agreement. Accordingly, this letter agreement records the agreement between the Parties relating to such grants of rights and termination of the Collaboration Agreement. 
  

	1)	Licensed Antigens – The Parties hereby agree that each Optioned Antigen of either Party under the Collaboration Agreement immediately prior to the date this
letter is acknowledged by AFI (the “Effective Date”) shall be deemed a Licensed Antigen for purposes of this letter agreement. The Parties further agree that as of the Effective Date the CuraGen Licensed Antigens consist of those antigens
set forth on Schedule 1, and the ABX Licensed Antigens consist of those antigens set forth on Schedule 2. 

  

 1 

	2)	Termination – By mutual agreement of the Parties, as of the Effective Date, the Collaboration Agreement will be irrevocably terminated and will be of no further
force or effect; provided, however that Sections 8, 9, 11, 12.1, 12.3, 12.4, 12.5, 12.6, 12.7, 13 and 15 of the Collaboration Agreement, together with any definitions necessary to give effect to the terms of this letter agreement,
shall survive such termination; and provided further that each reference to a Party’s Licensed Antigen or Optioned Antigen in any such surviving provision shall be deemed to refer to all of such Party’s Licensed Antigens as
listed in Schedule 1 or 2 hereto, as applicable. The Parties expressly acknowledge and agree that this termination is by mutual agreement of the Parties. 

  

	3)	Royalties Payable by CuraGen – By mutual agreement of the Parties, as of the Effective Date, the Collaboration Agreement will be amended such that Article 8 of
the Collaboration Agreement shall be deleted in its entirety and replaced with the following: 

 “Curagen shall pay Amgen
any payments that Amgen reasonably believes are required to be made under the Third Party License Agreements, including but not limited to any royalty and/or milestone payment thereunder. For the purposes of this Agreement, “Third Party License
Agreements” shall mean (a) that certain License Agreement dated May 14, 2002 between Babraham Bioscience Technologies Limited and Amgen Fremont Inc. (successor in interest to Abgenix, Inc.); (b) that certain License Agreement
with effective date of December 14, 1998, between Amgen Fremont Inc. (successor in interest to Abgenix, Inc.) and Medical Research Council; and (c) that certain License Agreement dated March 29, 1994, by and between Medical Research
Council, Agricultural and Food Research Council Institute of Animal Physiology and Genetics Research of Babraham Hall, Marianne Bruggeman c/o Institute of Animal Physiology and Genetics Research and Cell Genesys, Inc.” 
  

	4)	Grant of Rights 

  

	 	a)	Upon the Effective Date, CuraGen hereby grants to AFI an exclusive worldwide license (or sublicense, as the case may be) (with the right to grant sublicenses) under Licensed CuraGen
Intellectual Property to research, develop, make, have made, use, import, offer to sell and sell ABX Products. “ABX Products” shall mean, with respect to any ABX Licensed Antigen, any product comprising (a) an Antibody which binds to
such ABX Licensed Antigen; or (b) Genetic Material that encodes such Antibody, wherein, in respect of each ABX Product, said Genetic Material does not encode multiple antibodies. 

  

	 	b)	Upon the Effective Date, AFI: 

  

	 	i)	shall deliver to CuraGen (a) all Antigen Specific Materials and Information in its possession pertaining to CuraGen Licensed Antigens, (b) all patent filings pertaining to
or claiming CuraGen Licensed Antigens, and (c) all related Confidential Information of ABX or of CuraGen in AFI’s possession, and such Antigen Specific Materials and Information, patent filings and Confidential Information shall thereafter
be the Confidential Information of CuraGen; 

  

 2 

	 	ii)	hereby grants to CuraGen an exclusive worldwide license (or sublicense, as the case may be) (with the right to grant sublicenses) under Licensed ABX Intellectual Property Controlled
by AFI to research, develop, make, have made, use, import, offer to sell and sell CuraGen Products. “CuraGen Products” shall mean, with respect to any CuraGen Licensed Antigen, any product comprising (a) an Antibody which binds to
such CuraGen Licensed Antigen; or (b) Genetic Material that encodes such Antibody, wherein, in respect of each CuraGen Product, said Genetic Material does not encode multiple antibodies. For the purposes of this Agreement, “Control”
shall mean with respect to any intellectual property rights to which AFI has or obtains rights, possession by AFI or its Affiliate of the ability (whether by ownership, license or otherwise) to grant access, a license or a sublicense to such
intellectual property right as provided for in this Agreement (i) without violating the terms of any agreement with any Third Party and (ii) without requiring any further payment (whether or not then due and payable) under any agreement
with any Third Party (unless CuraGen elects in writing to pay any amounts owed to such Third Party under any such agreement by reason of CuraGen’s exploitation of CuraGen Products). For the sake of clarity, CuraGen has specifically elected to
pay any amounts owing under the Third Party License Agreements referenced in Paragraph 3 (Royalties Payable by CuraGen). 

  

	4)	 Release – In consideration of the mutual promises contained herein, each Party, for itself and for each of its Affiliates, hereby generally,
irrevocably, unconditionally and completely releases and forever discharges the other Party, such other Party’s Affiliates, and its and their officers, directors, stockholders, agents, employees, heirs, administrators, executors, predecessors,
successors and assigns (hereinafter, the “Released Parties”) from, and hereby irrevocably, unconditionally and completely waives and relinquishes, each of such Party’s Released Claims. The Parties acknowledge they are aware that they
may hereafter discover facts in addition to or different from those now known or believed to be true with respect to the subject matter of this release, but that it is their intention to hereby fully, finally and forever settle and release all such
claims, disputes and differences, known or unknown, suspected or unsuspected, that now exist or heretofore have existed between the Parties and that in furtherance of such intention, this release shall remain in effect as a full and complete release
notwithstanding the discovery or existence of any such additional or different facts. The term “Released Claims,” when used herein with respect to a Party, shall mean and include each and every claim, charge, complaint, demand, action,
cause of action, suit, right, debt, sum of money, cost, reckoning, covenant, contract, agreement, promise, doing, omission, damage, execution, obligation, liability, and expense (including attorneys’ fees and costs), of every kind and nature,
whether at law or in equity, that such Party may have had in the past, may now have or may have in the future against the Released Parties, and which has arisen or arises directly or indirectly out of, or relates directly or indirectly to, any
circumstance, agreement, activity, action, omission, event or matter occurring or 

  

 3 

	 	 
existing on or prior to the Effective Date to the extent such claim relates to or arises under the Collaboration Agreement; provided, however, that the
Released Claims shall exclude: (1) any and all rights to seek and obtain indemnification under this letter agreement and the Collaboration; and (2) any and all rights to seek and obtain enforcement of, or a remedy arising out of the breach
of, any obligation provided for in this letter agreement. 

  

	5)	Miscellaneous 

  

	 	a)	This letter agreement shall be binding upon the Parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly
authorized representatives of the Parties hereto. This letter agreement is binding upon and shall inure to the benefit of the Parties and their respective agents, assigns, heirs, executors, successors and administrators. 

  

	 	b)	No delay or omission by either Party in exercising any right under this letter agreement shall operate as a waiver of that or any other right. A waiver or consent given by a Party
on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

  

	 	c)	Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts,
terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement. 

  

	 	d)	This letter agreement shall be interpreted and construed by the laws of the State of Delaware without regard to its choice of law principles. 

  

	 	e)	This letter agreement contains and constitutes the entire understanding and agreement between the Parties hereto with respect to the subject matter hereof and cancels all previous
oral and written negotiations, agreements, commitments, writings in connection therewith. 

 Please sign and date this letter agreement in the
space provided below to confirm our mutual understandings and agreements as set forth in this letter agreement and return a signed copy to the undersigned. 
  

			
	Sincerely,
	
	CuraGen Corporation
		
	By:	 	 /s/ Tim Shannon

	Name:	 	Tim Shannon
	Title:	 	President and CEO

  

 4 

			
	ACKNOWLEDGED AND AGREED
	
	AMGEN FREMONT INC.
		
	By:	 	 /s/ Thomas Boone

	Name:	 	Thomas Boone
	Title:	 	Vice President, Protein Sciences
	
	5/1/09                                
	Date

  

 5 

 Schedule 1 
 CuraGen Licensed Antigens 
 CR002 
 CR005 
 CR007 
 CR010 
 CR011 
 CR012 
 CR014 
 CR017 
 CR032 
 CR064 
 CR074 
 CR105 
  

 6 

 Schedule 2 
 ABX Licensed Antigens 
 CR026 
 CR031 
 CR039 
 CR106 
 CR109 
 CR110 
  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00161-of-00352.parquet"}]]